Gilead Sciences Aktie
| 151,77USD | -4,03USD | -2,59% |
WKN: 885823 / ISIN: US3755581036
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 14 400 | 17 000 | 18 000 | 17 600 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,90 | 1,59 | 1,50 | 1,63 | 0,00 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 14 772 | 14 443 | 16 085 | 19 173 | 19 886 |
| Summe Anlagevermögen | 53 180 | 48 728 | 46 040 | 39 822 | 39 137 |
| Summe Aktiva | 67 952 | 63 171 | 62 125 | 58 995 | 59 023 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 46 888 | 41 962 | 39 376 | 39 749 | 36 405 |
| Summe Eigenkapital | 21 064 | 21 209 | 22 749 | 19 246 | 22 618 |
| Summe Passiva | 67 952 | 63 171 | 62 125 | 58 995 | 59 023 |
Adresse
| 333 Lakeside Drive, 94404 Foster City | |
| Telefon | +1 (650) 574-3000 |
| Fax | +1 (650) 522-5853 |
| Internet | http://www.gilead.com |
Management
|
Andrew D. Dickinson
Chief Financial Officer |
|
Anthony Welters
Lead Independent Director |
|
Cindy Perettie
Executive Vice President-Kite |
|
Daniel P. O'Day
Chairman & Chief Executive Officer |
|
Dietmar P. Berger
Chief Medical Officer |
|
Erin Burkhart
Chief Accounting Officer, Senior VP & Controller |
|
Flavius Martin
Executive Vice President-Research |
|
Harish M. Manwani
Independent Director |
|
Jacqueline K. Barton
Independent Director |
|
Jacquie Ross
Head-Investor Relations |
|
Janet Dorling
Senior VP- Intercontinental Region |
|
Javier J. Rodriguez
Independent Director |
|
Jeffrey A. Bluestone
Independent Director |
|
Johanna Mercier
Chief Commercial Officer & Corporate Affairs |
|
Joydeep Ganguly
Senior Vice President-Corporate Operations |
|
Jyoti K. Mehra
Executive Vice President-Human Resources |
|
Keeley Wettan
General Counsel, Executive VP-Legal & Compliance |
|
Kelly A. Kramer
Independent Director |
|
Linda Slanec Higgins
Senior VP-Research & External Innovation |
|
Robert D. Cook
Vice President |
|
Robert L. Mecca
Senior Vice President-Finance |
|
Sandra J. Horning
Independent Director |
|
Sarah C. Pope Miksinski
Executive Director-CMC Regulatory Affairs |
|
Stacey Y. Ma
EVP-Pharmaceutical Development & Manufacturing |
|
Ted W. Love
Independent Director |
|
Tomas Cihlar
Vice President-Virology |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.